review glp-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 and the kidney: from

Conversely, an episode of shedding may reveal previously compensated follicular miniaturization, leaving persistent patterned loss after the acute process resolves

This reduced sensitivity of muscles to insulin in obesity results in an increased breakdown of muscle protein and, subsequently, muscle loss

However, it's important to consider the potential long-term effects of using ColonBroom

As the levels of the medication in your blood begin to slowly decline, your appetite may return slightly, and nausea usually vanishes

An early RCT in 44 patients with obesity and subclinical binge eating showed that liraglutide was better than diet and exercise alone in reducing binge-eating scores at 12 weeks 220 , but a later investigation of 27 adults with BED comparing liraglutide against placebo did not find any differences in the number of binging episodes over 17 weeks 218

Horowitz T, Pellerin L, Zimmer ER, Guedj E